Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma

Launched by DR.DR.IRMA BERNADETTE, SPKK (K) · Dec 7, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a treatment called the Pigment Solution Program (PSP) for women with melasma, a skin condition that causes dark patches on the face. The research is taking place at two dermatology centers in Indonesia and aims to see how well PSP works as an additional treatment for melasma.

To join the study, participants need to be women aged 30 to 60 years with specific skin types and diagnosed with melasma. Unfortunately, women who are pregnant, breastfeeding, or using other skin lightening treatments won't be able to participate. If eligible, participants can expect to receive the PSP treatment and be monitored for any side effects or improvements in their skin condition. This trial is an important step in understanding better options for managing melasma.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. women aged 30-60 years
• • 2. Fitzpatrick skin phototype IV-V
• • 3. Diagnosis of epidermal, mixed and dermal types of Melasma
• Exclusion Criteria:
• • 1. Are pregnant or breastfeeding
• • 2. Use other lightening agents, both oral and topical
• • 3. Allergy to PSP content
• • 4. Use of other topical therapies for skin disorders may interfere with the evaluation of melasma conditions
• • 5. Suffering from other skin diseases such as acne, dermatitis
• • 6. Using hormonal birth control